CACS Numbers as of 7/25/04:
Book Value = $5.097
Market Cap = $237.7M
Total Cash = $118.1M
Cash flow positive - generated about 12¢ a share last Q
Share Price = $7 less $3.75 cash = $3.25
LT Debt = $0
TTM PE = 42
2004 Earnings = $0.40, PE = $3.25 / $0.40 = 8.1
2005 Earnings = $0.60, PE = $3.25 / $0.60 = 5.4
2004 Year-over-year Revenue up over 100%
Market for main product expected to double in the next few years
Price/Sales = 2.5
Price/Sales with Cash removed from price = 1.5
Short term, anything can happen, but if they were not lying or hiding information during the conference call then the numbers above tell a different story than the recent price decline.
The markets are “murky” about the future of the economy and terrorism, so CACS seems to have discounted itself to the low end of the range I gave numbers for calculating here
http://www.investorshub.com/boards/read_msg.asp?message_id=1615728
Zaphod used those numbers to show a fair market range of $8 to $16 here:
http://www.investorshub.com/boards/replies.asp?msg=1615728
$8 was for no growth premium and $16 for a growth premium.
The range the past 6 months has been $7 to $18… pretty much as calculated 9 months ago!
Kirk out
#board-1574
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM